Edwards Lifesciences develops structural heart technologies, particularly minimally invasive therapies for heart valve disease. Its products include transcatheter aortic valve replacement systems, transcatheter mitral and tricuspid therapies, and related procedural technologies. Its revenue is closely tied to cardiovascular procedure volumes, clinical adoption, and access to treatments for patients with structural heart conditions.
Edwards Lifesciences Corp. (EW) has a MarketKingdoms composite score of 63.9 (B-), an B-range rating. It ranks 931st of 1,866 covered companies, 43rd of 78 in Healthcare (sector average 64.5) and 2nd of 10 in Medical Devices. Scores as of 2026-10-25.
Its strongest lenses are KPI momentum at 81 (Healthcare average 78) and Catalyst watch at 80 (Healthcare average 74). Its weakest lenses are Price (valuation) at 27 (sector average 50) and Trend (momentum) at 41 (sector average 50).
| Lens | Type | EW | Healthcare average | Medical Devices average | Percentile in sector |
|---|---|---|---|---|---|
| Industry opportunity | Research signal | 77 | 81 | 77 | 44th |
| Stock selection | Research signal | 79 | 79 | 78 | 44th |
| KPI momentum | Research signal | 81 | 78 | 75 | 56th |
| Catalyst watch | Research signal | 80 | 74 | 75 | 91st |
| Price (valuation) | Fundamental lens | 27 | 50 | 54 | 19th |
| Expansion (growth) | Fundamental lens | 68 | 50 | 57 | 82nd |
| Quality (profitability) | Fundamental lens | 69 | 50 | 53 | 78th |
| Trend (momentum) | Fundamental lens | 41 | 50 | 27 | 38th |
The most recent call analysed was held on 2026-07-23 (fiscal 2026 Q2). MarketKingdoms checks what management promised on each call against what it later delivered.
The stock's valuation gap is +1.7%: its price is in line with the path its market, sector and industry moves explain. Factor sensitivity: market beta 0.78, sector beta 0.33, industry beta 0.50; the factor model explains 44% of its moves (R²).
| Company | Composite | Grade | Valuation gap |
|---|---|---|---|
| DexCom Inc. (DXCM) | 70.2 | B+ | -25.0% |
| STERIS plc (STE) | 63.9 | B- | -7.7% |
| Zimmer Biomet Holdings Inc. (ZBH) | 62.7 | B- | -12.1% |
| Medtronic Plc (MDT) | 62.5 | B- | -5.9% |
| Abbott Laboratories (ABT) | 60.9 | B- | -6.4% |
| GE HealthCare Technologies Inc. (GEHC) | 60.4 | B- | -5.8% |
| Insulet Corp. (PODD) | 59.2 | B- | -18.8% |
| Stryker Corp. (SYK) | 59.2 | B- | -3.3% |
Edwards Lifesciences Corp. financial statements · Healthcare sector ranking · Medical Devices industry ranking · All covered companies
The composite score (0–100, graded A+ to D-) blends research signals from each earnings call with fundamental lenses from SEC filings and market prices. Research signals: Industry opportunity, Stock selection, KPI momentum and Catalyst watch, read from what management said and whether it delivered. Fundamental lenses: Price (valuation), Expansion (growth), Quality (profitability) and Trend (momentum). Scores are recalculated every night and after every earnings call. The valuation gap compares the actual price path with the path the stock's market, sector and industry moves explain; it is a model comparison, not a fair-value estimate.
General information, not investment advice.